TAK vs. PFE, SNY, VRTX, REGN, GSK, BMY, ZTS, TEVA, ALNY, and GMAB
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Pfizer (PFE), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), GSK (GSK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical preparations" industry.
Pfizer (NYSE:PFE) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
In the previous week, Pfizer had 29 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 35 mentions for Pfizer and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.68 beat Pfizer's score of 0.27 indicating that Pfizer is being referred to more favorably in the media.
Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.9%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 47.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 15 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
68.4% of Pfizer shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Pfizer received 1389 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 69.06% of users gave Pfizer an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Pfizer is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Takeda Pharmaceutical has a net margin of 6.18% compared to Takeda Pharmaceutical's net margin of -0.56%. Pfizer's return on equity of 9.92% beat Takeda Pharmaceutical's return on equity.
Pfizer has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Pfizer presently has a consensus target price of $35.86, indicating a potential upside of 25.11%. Takeda Pharmaceutical has a consensus target price of $14.00, indicating a potential upside of 4.87%. Given Takeda Pharmaceutical's higher possible upside, equities research analysts clearly believe Pfizer is more favorable than Takeda Pharmaceutical.
Summary
Pfizer beats Takeda Pharmaceutical on 15 of the 20 factors compared between the two stocks.
Get Takeda Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Takeda Pharmaceutical Competitors List
Related Companies and Tools
